http://rdf.ncbi.nlm.nih.gov/pubchem/patent/WO-2017219078-A1
Outgoing Links
| Predicate | Object |
|---|---|
| assignee | http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_93d4be1122ac19a1f6b4b45a73b1645f |
| classificationCPCAdditional | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K2319-50 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K2319-21 |
| classificationCPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K38-37 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N33-68 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N33-6893 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N33-86 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K14-755 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K35-16 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P7-04 |
| classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P7-04 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K38-37 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07K1-113 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07K14-755 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/G01N33-68 |
| filingDate | 2017-06-20-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor | http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_4159ecf1567739ca66cbf04e991ebf13 |
| publicationDate | 2017-12-28-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | WO-2017219078-A1 |
| titleOfInvention | Allosteric regulation of haemostatic activity |
| abstract | The present invention relates to the discovery of the importance of the vicinal cysteine residues located in von Willebrand factor (VWF) domain A2. Thus the invention discloses modified VWF wherein: (a) the vicinal cysteine residues of VWF domain A2 are replaced by selenocysteine to enable the formation of a covalent bond between the adjacent selenocysteine moieties; (b) the vicinal cysteines of VWF domain A2 are chemically oxidised (i.e. linked via a covalent disulfide bond) thereby increasing the relative abundance of oxidised VWF in a composition; (c) the vicinal cysteine residues of VWF domain A2 are replaced by amino acids other than cysteine or selenocysteine in order to abrogate the formation of a covalent bond in the A2 region; and (d) the vicinal cysteines of VWF domain A2 are chemically reduced thereby increasing the relative abundance of reduced VWF in a composition. Said proteins and compositions are useful for the treatment of von Willebrand disease and acquired von Willebrand syndrome. |
| priorityDate | 2016-06-20-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 383.